Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2012

01-09-2012 | Review Article

Leptin and breast cancer: an overview

Authors: Mehmet Artac, Kadri Altundag

Published in: Medical Oncology | Issue 3/2012

Login to get access

Abstract

Leptin is a well-known mediator of obesity. Leptin and its receptor are overexpressed in breast cancer, especially in high-grade tumors. It has an association with progression and poor survival of breast cancer. Leptin can regulate endothelial cell proliferation and promote angiogenesis. There are several other factors such as insulin and HER2 may be involved in the relationship between leptin and breast cancer. Leptin system has emerged as a new and promising therapeutic target for breast cancer. This review article summarizes the current knowledge about the relation of leptin and breast cancer.
Literature
1.
Schapira DV, Kumar NB, Lyman GH, Cox CE. Obesity and body fat distribution and breast cancer prognosis. Cancer. 1991;67:523–8.PubMedCrossRef
2.
Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ. 2007;335:1134.PubMedCrossRef
3.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32.PubMedCrossRef
4.
Schwartz MW, Baskin DG, Kaiyala KJ, Woods SC. Model for the regulation of energy balance and adiposity by the central nervous system 1–3. Am J Clin Nutr. 1999;69:584–96.PubMed
5.
Goodwin PJ, Ennis M, Fantus IG, et al. Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol. 2005;23:6037–42.PubMedCrossRef
6.
Garaulet M, Pérex-Llamas F, Fuente T, et al. Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol. 2000;143:657–66.PubMedCrossRef
7.
Surmacz E. Obesity hormone leptin: a new target in breast cancer? Breast Cancer Res. 2007;9:301.PubMed
8.
Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res. 2004;10:4325–31.PubMedCrossRef
9.
Ray A, Nkhata KJ, Cleary MP. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol. 2007;30:1499–509.PubMed
10.
Bozcuk H, Uslu G, Samur M, et al. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine. 2004;27:58–65.PubMedCrossRef
11.
Hollmann M, Runnebaum B, Gerhard I. Impact of waist-hip-ratio and body-mass-index on hormonal and metabolic parameters in young, obese women. Int J Obes Relat Metab Disord. 1997;21:476–83.PubMedCrossRef
12.
Borugian MJ, Sheps SB, Kim-Sing C, et al. Waist to hip ratio and breast cancer mortality. Am J Epidemiol. 2003;158:963–8.PubMedCrossRef
13.
Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292–5.PubMedCrossRef
14.
15.
Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell. 2005;83:1263–71.CrossRef
16.
Catalano S, Marsico S, Giordano C, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 2003;278:28668–76.PubMedCrossRef
17.
Geisler C, Haynes B, Ekse D, et al. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. J Streoid Biochem Mol Biol. 2007;104:27–34.CrossRef
18.
Rose DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin. Int J Oncol. 2002;21:1285–92.PubMed
19.
Hamilton BS, Paglia D, Kwan AY, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med. 1995;1:953–6.PubMedCrossRef
20.
Cirillo D, Rachiglio AM, Montagna R, et al. Leptin signaling in breast cancer: an overview. J Cell Biochem. 2008;105:956–64.PubMedCrossRef
21.
O’Brien SN, Welter BH, Price TM. Presence of leptin in breast cell lines and breast tumors. Biochem Biophys Res Commun. 1999;259:695–8.PubMedCrossRef
22.
White DW, Tartaglia LA. Evidence for ligand-independent homo-oligomerization of leptin receptor (OB-R) isoforms: a proposed mechanism permitting productive long-form signaling in the presence of excess short-form expression. J Cell Biochem. 1999;73:278–88.PubMedCrossRef
23.
Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem. 1997;272:32686–95.PubMedCrossRef
24.
25.
Fong TM, Huang RR, Tota MR, et al. Localization of leptin binding domain in the leptin receptor. Mol Pharmacol. 1998;53:234–40.PubMed
26.
Hileman SM, Tornoe J, Flier JS, Bjorbaek C. Transcellular transport of leptin by the short leptin receptor isoform ObRa in madin-darby canine kidney cells. Endocrinology. 2000;141:1955–66.PubMedCrossRef
27.
Huang L, Wang Z, Li C. Modulation of circulating leptin levels by its soluble receptor. J Biol Chem. 2011;276:6343–9.CrossRef
28.
Devos R, Guisez Y, Van der Heyden J, et al. Ligand-independent dimerization of the extracellular domain of the leptin receptor and determination of the stoichiometry of leptin binding. J Biol Chem. 1997;272:18304–10.PubMedCrossRef
29.
Yin N, Wang D, Zhang H, et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res. 2004;64:5870–5.PubMedCrossRef
30.
Bjorbaek C, Elmquist JK, Frantz JD, et al. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell. 1998;1:619–25.PubMedCrossRef
31.
Bjorbaek C, El-Haschimi K, Frantz JD, Flier JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem. 1999;274:30059–65.PubMedCrossRef
32.
Szanto I, Kahn CR. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. Proc Natl Acad Sci USA. 2000;97:2355–60.PubMedCrossRef
33.
Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science. 1998;281:1683–6.PubMedCrossRef
34.
Park HY, Kwon HM, Lim HJ, et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med. 2011;33:95–102.
35.
Garonna E, Botham KM, Birdsey GM, et al. Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PLoS ONE. 2011;6:e18823.PubMedCrossRef
36.
Gonzalez RR, Cherfils S, Escobar M, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem. 2006;281:26320–8.PubMedCrossRef
37.
Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer. 2011;104:128–37.PubMedCrossRef
38.
39.
Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and antropometric measures. Am J Clin Nutr. 2001;74:295–301.PubMed
40.
Jarde T, Caldefie-Chezet F, Damez M, et al. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep. 2008;19:905–11.PubMed
41.
Revillion F, Charlier M, Lhotellier V, et al. Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin Cancer Res. 2006;12:2088–94.PubMedCrossRef
42.
Ozet A, Arpacı F, Yilmaz MI, et al. Effects of tamoxifen on the serum leptin level in patients with breast cancer. Jpn J Clin Oncol. 2001;31:424–7.PubMedCrossRef
43.
Catalano S, Mauro L, Marsico S, et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor α in MCF-7 cells. J Biol Chem. 2004;279:19908–15.PubMedCrossRef
44.
O’Neil JS, Burow ME, Green AE, et al. Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors α and β. Mol Cell Endocrinol. 2001;176:67–75.PubMedCrossRef
45.
Garafalo C, Sisci D, Surmacz E. Leptin interferes with the effects of the antiestrogen ICI 182, 780 in MCF-7 breast cancer cells. Clin Cancer Res. 2004;10:6466–75.CrossRef
46.
Kim Y, Kim SY, Lee JJ, et al. Effects of the expression of leptin and leptin receptor (OBR) on the prognosis of early-stage breast cancers. Cancer Res Treat. 2006;38:126–32.PubMedCrossRef
47.
Artac M, Bozcuk H, Kıyıcı A, Eren OO, Boruban MC, Ozdogan M. Correlation of serum leptin level and waist-to-hip ratio (WHR) with overall survival of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AIs). ASCO Annual Meetings Proceedings, 2010, Abstract. 1106, Chicago, USA.
48.
Nunez NP, Jelovac D, Macedo L, et al. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. Clin Cancer Res. 2004;10:5375–80.PubMedCrossRef
49.
Geisler J, Ekse D, Lonning PE (2006) The aromatase inactivator exemestane decreases plasma leptin levels in postmenopausal breast cancer patients. AACR, 97th Annual Meeting, 2006, Abstract 420, Washington DC, USA.
50.
Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999;9:125–38.PubMedCrossRef
51.
Eisenberg A, Biener E, Charlier M, et al. Transactivation of erbB2 by short and long isoforms of leptin receptors. FEBS Lett. 2004;565:139–42.PubMedCrossRef
52.
Fiorio E, Mercanti A, Terrasi M, et al. Leptin/HER2 crosstalk in breast cancer: in vitro study, preliminary in vivo analysis. BMC Cancer. 2008;8:305.PubMedCrossRef
53.
Soma D, Kitayama J, Yamashita H, et al. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res. 2007;149:9–14.PubMedCrossRef
54.
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.PubMedCrossRef
55.
Otvos L Jr, Kovalszky I, Riolfi M, et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 2011;47:1578–84.PubMedCrossRef
56.
Vona-Davis L, Rose DP, Howard-McNatt M, et al. Triple-negative breast cancer and obesity in a rural appalachian population. Cancer Epidemiol Biomarkers Prev. 2008;17:3319–24.PubMedCrossRef
57.
Maiti B, Kundranda MN. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat. 2010;121:479–83.PubMedCrossRef
58.
Oh SW, Park CY, Lee ES, et al. Adipokines, insulin resistance, metabolic syndrome, breast cancer recurrence: a chort study. Breast Cancer Res. 2011;13:R34.PubMedCrossRef
59.
Nyante SJ, Gammon MD, Kaufman JS, et al. Common genetic variation in adiponectin, leptin and leptin receptor and associations with breast cancer subtypes. Breast Cancer Res Treat 2011 Apr 23. [Epub ahead of print].
Metadata
Title
Leptin and breast cancer: an overview
Authors
Mehmet Artac
Kadri Altundag
Publication date
01-09-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0056-0

Other articles of this Issue 3/2012

Medical Oncology 3/2012 Go to the issue

Review

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement

Original Paper

Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study

Original Paper

Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis

Letter to the Editor

P53 protein profile by IHC may be helpful to define patient prognosis

Original Paper

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial

Original Paper

Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits